Psyence Biomedical Ltd (PBM) FinancialsPBMPsyence Biomedical Ltd

In the context of the broader market, PBM competes directly with industry leaders such as NRSN and AEON. With a market capitalization of $13.27M, it holds a significant position in the sector. When comparing efficiency, PBM's gross margin of N/A stands against NRSN's N/A and AEON's N/A. Such benchmarking helps identify whether Psyence Biomedical Ltd is trading at a premium or discount relative to its financial performance.

Psyence Biomedical reported a net income of -753,254 USD for Q2 2026, showing a decline from a positive net income of 141,473 USD in Q2 2025. The EPS for Q2 2026 is -3.18, indicating losses per share.